BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Vous n'êtes pas connecté
Lyell Immunopharma, Inc, a clinical─stage T─cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumours or haematologic malignancies, reported the initial data from
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
PHOENIX — Statistics & Data Corporation (SDC), a global leader in life sciences biometrics services and technology solutions, announces the...
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...